These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 38926935

  • 1. Gestational weight gain and adverse birth outcomes in South African women with HIV on antiretroviral therapy and without HIV: a prospective cohort study.
    Madlala HP, Myer L, Jao J, Geffen H, Matjila M, Fisher A, Meyer D, Werner EF, Petro G, Cu-Uvin S, McGarvey ST, Bengtson AM.
    J Int AIDS Soc; 2024 Jun; 27(6):e26313. PubMed ID: 38926935
    [Abstract] [Full Text] [Related]

  • 2. The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study.
    Gedefaw A, Tadesse BT, Berhan Y, Makonnen E, Vella S, Aklillu E.
    BMC Infect Dis; 2024 Sep 02; 24(1):901. PubMed ID: 39223552
    [Abstract] [Full Text] [Related]

  • 3. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, Gaolethe T, Petlo C, Lockman S, Holmes LB, Makhema J, Shapiro RL.
    Lancet Glob Health; 2018 Jul 02; 6(7):e804-e810. PubMed ID: 29880310
    [Abstract] [Full Text] [Related]

  • 4. Elevated body mass index during pregnancy and gestational weight gain in HIV-infected and HIV-uninfected women in Cape Town, South Africa: association with adverse birth outcomes.
    Madlala HP, Malaba TR, Newell ML, Myer L.
    Trop Med Int Health; 2020 Jun 02; 25(6):702-713. PubMed ID: 32133728
    [Abstract] [Full Text] [Related]

  • 5. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.
    Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S, IMPAACT 2010/VESTED Study Team .
    Clin Infect Dis; 2024 Jun 14; 78(6):1617-1628. PubMed ID: 38180851
    [Abstract] [Full Text] [Related]

  • 6. An observational cohort study to investigate the impact of dolutegravir in pregnancy and its obesogenic effects on the metabolic health of women living with HIV and their children: Study protocol.
    Abrams EJ, Jao J, Madlala HP, Zerbe A, Catalano P, Gerschenson M, Goedecke JH, Gomba Y, Josefson J, Kurland IJ, Legbedze J, McComsey GA, Matyesini S, Mukonda E, Robinson D, Myer L.
    PLoS One; 2024 Jun 14; 19(8):e0307296. PubMed ID: 39159183
    [Abstract] [Full Text] [Related]

  • 7. Gestational weight gain during the second and third trimesters and adverse pregnancy outcomes, results from a prospective pregnancy cohort in urban Tanzania.
    Yang J, Wang M, Tobias DK, Rich-Edwards JW, Darling AM, Abioye AI, Pembe AB, Madzorera I, Fawzi WW.
    Reprod Health; 2022 Jun 16; 19(1):140. PubMed ID: 35710384
    [Abstract] [Full Text] [Related]

  • 8. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, Seden K, Hodel EM, Chen T, Twimukye A, Byamugisha J, Reynolds H, Watson V, Burger D, Wang D, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S, DolPHIN-2 Study Group.
    Lancet HIV; 2020 May 16; 7(5):e332-e339. PubMed ID: 32386721
    [Abstract] [Full Text] [Related]

  • 9. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, van Wyk-Heath M, Mthethwa S, Shai S, Mngomezulu NN, Tlhowe L, Achere-Darko J, Bedford J, Martin CE, Fairlie L, Imrie J.
    HIV Med; 2024 Jul 16; 25(7):826-839. PubMed ID: 38520085
    [Abstract] [Full Text] [Related]

  • 10. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    Patel K, Huo Y, Jao J, Powis KM, Williams PL, Kacanek D, Yee LM, Chadwick EG, Shiau S, Jacobson DL, Brummel SS, Sultan-Beyer L, Kahlert CR, Zash R, Seage GR, Pediatric HIV/AIDS Cohort Study, Swiss Mother and Child HIV Cohort Study.
    N Engl J Med; 2022 Sep 01; 387(9):799-809. PubMed ID: 36053505
    [Abstract] [Full Text] [Related]

  • 11. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A, Kusejko K, Johnson LF, Günthard HF, Riou J, Wandeler G, Egger M, Kouyos RD.
    PLoS Med; 2020 Dec 01; 17(12):e1003397. PubMed ID: 33315863
    [Abstract] [Full Text] [Related]

  • 12. Antiretroviral therapy use during pregnancy and adverse birth outcomes in South African women.
    Malaba TR, Phillips T, Le Roux S, Brittain K, Zerbe A, Petro G, Ronan A, McIntyre JA, Abrams EJ, Myer L.
    Int J Epidemiol; 2017 Oct 01; 46(5):1678-1689. PubMed ID: 29040569
    [Abstract] [Full Text] [Related]

  • 13. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saϊdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D, ODYSSEY Trial Team.
    BMC Infect Dis; 2021 Jan 04; 21(1):5. PubMed ID: 33446115
    [Abstract] [Full Text] [Related]

  • 14. Patterns and predictors of gestational weight gain in Addis Ababa, Central Ethiopia: a prospective cohort study.
    Asefa F, Cummins A, Dessie Y, Foureur M, Hayen A.
    Reprod Health; 2021 Jul 28; 18(1):159. PubMed ID: 34321037
    [Abstract] [Full Text] [Related]

  • 15. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
    Ashta KK, Arora S, Khanna R, Raman N, Anilkumar A, Mohan C.
    Curr HIV Res; 2024 Jul 28; 22(1):31-46. PubMed ID: 38284697
    [Abstract] [Full Text] [Related]

  • 16. Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa.
    Nyemba DC, Kalk E, Madlala HP, Malaba TR, Slogrove AL, Davies MA, Boulle A, Myer L, Powis KM.
    BMC Pregnancy Childbirth; 2021 May 04; 21(1):354. PubMed ID: 33947351
    [Abstract] [Full Text] [Related]

  • 17. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S.
    Lancet HIV; 2020 Mar 04; 7(3):e193-e200. PubMed ID: 32035041
    [Abstract] [Full Text] [Related]

  • 18. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA, Miller S, Childs-Kean LM.
    Ann Pharmacother; 2020 Dec 04; 54(12):1252-1259. PubMed ID: 32517480
    [Abstract] [Full Text] [Related]

  • 19. Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.
    Manne-Goehler J, Fabian J, Sokhela S, Akpomiemie G, Rahim N, Lalla-Edward ST, Brennan AT, Siedner MJ, Hill A, Venter WDF.
    J Int AIDS Soc; 2024 Jul 04; 27(7):e26268. PubMed ID: 38978403
    [Abstract] [Full Text] [Related]

  • 20. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.
    Maphosa T, Dunga S, Makonokaya L, Woelk G, Maida A, Wang A, Ahimbisibwe A, Chamanga RK, Zimba SB, Kayira D, Machekano R.
    BMC Public Health; 2024 May 16; 24(1):1321. PubMed ID: 38755632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.